arrow
T

Tomi Jun

ica hn school of medicine at mount sinai
H指数:24
被引数:1,941

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial (vol 29, pg 2825, 2023)
2024-01-191
OAAI
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Divarasib联合西妥昔单抗治疗KRAS G12C-positive结直肠癌: 1b期临床试验

2023-12-0531
OAAI
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
2023-10-0233
OAAI
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

肝细胞癌免疫检查点抑制后的进展模式和治疗测序: 一项国际观察性研究

2023-01-1318
OAAI
Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
2022-08-0115
OAAI
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
2022-04-2813
OAAI
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice

治疗相关的毒性和肝细胞癌免疫治疗的改善结果: 来自FDA对具有里程碑意义的临床试验的汇总分析的证据,并通过常规实践进行验证

2021-11-0149
PREAI
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
2021-10-0838
OA
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer
2021-08-0623
OAAI
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
2021-04-2817
OAAI